Skip to main content
. 2017 Feb 10;5(3):346–350. doi: 10.1002/ccr3.839

Figure 1.

Figure 1

Plasma dabigatran concentration and thrombin time in patients treated with idarucizumab. The Hemoclot® Thrombin Inhibitor assay limit of quantification was defined as 30 ng/mL (red dotted line). (A) Plasma dabigatran concentration and thrombin time in patient 1 (gastrointestinal bleeding). (B) Plasma dabigatran concentration and thrombin time in patient 2 (gastrointestinal bleeding). (C) Plasma dabigatran concentration and thrombin time in patient 3 (intracerebral bleeding).